Atacicept 75 mg

DRUG4 trials

Sponsors

EMD Serono, EMD Serono Research & Development Institute, Inc.

Conditions

IgA NephropathyLupus Erythematosus, SystemicRelapsing Multiple Sclerosis

Phase 2

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

CompletedNCT00624338

EMD SeronoLupus Erythematosus, Systemic

Start: 2008-01-31End: 2012-10-31Updated: 2016-03-14

Atacicept in Multiple Sclerosis Extension Study, Phase II

TerminatedNCT00853762

EMD SeronoRelapsing Multiple Sclerosis

Start: 2009-03-31End: 2011-02-28Updated: 2017-03-20

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

TerminatedNCT02070978

EMD SeronoLupus Erythematosus, Systemic

Start: 2014-07-29End: 2018-02-09Updated: 2019-03-21

Efficacy and Safety of Atacicept in IgA Nephropathy

TerminatedNCT02808429

EMD Serono Research & Development Institute, Inc.IgA Nephropathy

Start: 2017-01-31End: 2020-02-07Updated: 2021-02-25

Related Papers

#3848 ORIGIN TRIAL: 24-WK PRIMARY ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PH2B STUDY OF ATACICEPT IN PATIENTS WITH IGAN

Nephrology Dialysis Transplantation2023-06-0113 citations

Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.

2022-05-2671 citations

Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus

Lara D. Veeken2021-02-0424 citations

MO039THE 24-WEEK INTERIM ANALYSIS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF ATACICEPT IN PATIENTS WITH IGA NEPHROPATHY AND PERSISTENT PROTEINURIA

Nephrology Dialysis Transplantation2020-06-0113 citations

S7A:4 Reduction of systemic lupus flares by atacicept in a randomised, placebo-controlled, phase iib study (address ii) and its extension study

2018-03-01

Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).

2014-06-20224 citations

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

2014-03-06250 citations